Optimer Rides High After OPT-80 C. Diff Trial Success
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III data show antibiotic non-inferior to Vancocin; additional trial results due mid-2009 with an NDA filing by year’s end.
You may also be interested in...
Emboldened By Strong Data, Optimer Licenses Antibiotic Candidate To Astellas
Just days after the publication of promising data concerning its antibiotic drug candidate fidaxomicin, Optimer Pharmaceuticals Inc. has licensed the compound to Astellas Pharma Europe Ltd. to treat Clostridium difficile infections in Europe and additional territories
Emboldened By Strong Data, Optimer Licenses Antibiotic Candidate To Astellas
Phase III data showing an improved relapse rate relative to the standard of care drove the deal, which could be worth up to $214 million.
Emboldened By Strong Data, Optimer Licenses Antibiotic Candidate To Astellas
Phase III data showing an improved relapse rate relative to the standard of care drove the deal, which could be worth up to $214 million.